Unlock instant, AI-driven research and patent intelligence for your innovation.

Hemostatic

A drug and coagulation factor technology, applied in the field of snake venom kinase hemostatic drugs

Inactive Publication Date: 2004-08-18
北京诺维康医药科技有限公司
View PDF1 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The Chinese patent application CN1249338A published on April 5, 2000, "A Method for Efficiently Extracting Blood Coagulation Factor 10 Activating Enzyme" introduced that this product is used in scientific research fields such as the study of tumor migration mechanism, and the extracted and purified RVV-X is used for No report on hemostatic purpose
[0006] There is an imitation product of Lizhizhi in China - Baquting, but it needs to import the raw material - Brazilian spearhead snake (Bothrops atrox) poison

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hemostatic
  • Hemostatic
  • Hemostatic

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Prepare snake venom coagulase hemostatic drug according to the composition of prescription 2 in the above table: take coagulase 1U / ml, RVV-X 5U / ml, human serum albumin 20mg, mannitol 30mg according to the conventional method, and make it into freeze-dried Powder injection, the snake venom coagulase hemostatic drug for injection with a specification of 1ml / bottle.

Embodiment 2

[0089] Prepare snake venom coagulase hemostatic drug according to the composition of prescription 2 in the above table: take coagulase 0.8U / ml, RVV-X 1U / ml, human serum albumin 10mg, mannitol 30mg according to the conventional method, and make it into frozen Dry powder injection, the snake venom coagulase hemostatic drug for injection with a specification of 1ml / bottle.

Embodiment 3

[0091] According to the composition of prescription 2 in the above table, the snake venom coagulase hemostatic drug was prepared: take coagulase 0.01U / ml, RVV-X 0.1U / ml, human serum albumin 1mg, and mannitol 30mg according to the conventional method, and make it into Freeze-dried powder injection, the snake venom coagulase hemostatic drug for injection with a specification of 1ml / bottle.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is one kind snake venom cytozyme hemostatic containing blood coagulating factor, activator RVV-X and synergist snake venom thrombase. Preferably, the snake venom cytozyme hemostatic contains also serum albumin, for example human serum albumin. In addition, the present invention also discloses the preparation process and hemostatic use of high purity RVV-X.

Description

technical field [0001] The invention relates to a snake venom coagulase hemostatic drug, which contains a blood coagulation factor ten activator (RVV-X) and a synergist-thrombin-like enzyme (Thrombin-like Enzyme). More preferably, the hemostatic agent further contains serum albumin, such as human serum albumin. Background technique [0002] In 1934, Macfarlane et al. found that viper venom had a very significant coagulation effect. When it was diluted 1000 times, it could coagulate the blood of hemophiliacs in 17 seconds (see The Lancet, "DRS. MACFARLANE & BARNETT: HAEMOSSTATICPOSSIBILITIES OF SNAKE-VONOM" , Nov.3, 1934, pp. 985-987). It was used as local hemostasis for external use in some areas abroad in the early stage, such as hemostasis for pulling teeth (see The Lancet, "CLINICAL AND LABORATORY NOTES", Feb. 22, 1936, page 428), and use full poison, that is, no Stypven (Wellcome UK), the representative product of the isolated and purified primar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/43A61P7/04
Inventor 熊时泽
Owner 北京诺维康医药科技有限公司